Navigation Links
Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference

WHITE PLAINS, N.Y., Dec. 5 /PRNewswire-USNewswire/ -- Researchers funded by The Leukemia & Lymphoma Society will present exciting new directions in blood cancer research at the annual American Society of Hematology (ASH) conference this week at the Georgia World Congress Center in Atlanta. Especially noteworthy are new findings in immunotherapies, personalized medicine and targeting transcription factors.

Immunotherapies: Researchers will discuss the current status of anti- cancer vaccines for patients with B-cell lymphoma; results of early clinical trials on adoptive T-cell immunotherapies for B-cell malignancies; new understanding of how immune cells known as natural killer (NK) cells can eliminate cancer cells; and the emerging role of NK cells in stem cell transplantation.

-- Vaccines for Lymphomas: Idiotype Vaccines and Beyond, Larry Kwak, M.D.,

Ph.D., The University of Texas M.D. Anderson Cancer Center, Houston,

(Saturday, Dec. 8, 9:30 a.m.).

-- Engineering Antitumor Immunity by T-cell Adoptive Immunotherapy,

Stanley Riddell, M.D., Fred Hutchinson Cancer Research Center,

Seattle, WA, (Dec. 8, 9:30 a.m.).

-- Human Natural Killer Cell Biology, Michael Caligiuri, M.D., The Ohio

State University Comprehensive Cancer Center, Columbus, (Sunday,

Dec. 9, 7:30 a.m.).

-- The Role of Natural Killer Cells in Haploidentical Hematopoietic

Transplantation, Andrea Velardi, M.D., University of Perugia, Italy,

(Dec. 9, 7:30 a.m.).

Targeting transcription factors: Transcription factors are proteins that control gene expression. Abnormalities in transcription factor activity are among the most common causes of myeloid and lymphocytic leukemias and are good targets for new drug development.

-- Targeting RUNX1 in Leukemia, John H. Bushweller, Ph.D., University of

Virginia, Charlottesville; Targeting MLL Fusion Genes in Leukemia,

Michael Thirman, M.D., University of Chicago. (Same session: Dec. 8,

2 p.m., and Dec. 9, 7:30 a.m.).

Personalized medicine: Society-funded researchers are developing new tests to distinguish biological traits (biomarkers) in cancers to identify patients who are most likely to benefit from a particular treatment and enable doctors to personalize treatment.

-- Deoxycytidine Kinase Genotype Includes Leukemia Cell Concentration of

Cytarabine 5-Triphosphate in Pediatric AML Patients, Varsha Gandhi,

Ph.D., M.D. Anderson Cancer Center, (Monday, Dec. 10, 8 a.m.).

-- Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as

Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic

Leukemia, Shaomeng Wang, Ph.D., University of Michigan, (Dec. 10, 7:45


-- IgVH Mutational Status Does Not Affect Complete Remission Rate But Is

Associated with Reduced Remission Duration in CLL Patients Treated with

Fludarabine, Cyclophosphamide and Rituximab (FCR)-based Therapy, Thomas

Kipps, M.D., Ph.D., University of California, San Diego, (Tuesday,

Dec. 11, 8 a.m.).

Prior to the start of ASH, the Society will host this year's Marshall A. Lichtman Research Symposium, Chronic Lymphocytic Leukemia as a Model of Translational Research, on Friday, Dec. 7, 7 a.m., at the Omni Hotel at CNN Center in Atlanta. The program will feature several Society-funded researchers discussing all aspects of CLL, from causes to novel treatments.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572.

Contact: Andrea Greif


SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
3. Major grant advances UWs clinical and translational research enterprise
4. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
5. Innovation and Medical Advances to be Highlighted on Final Day of Inaugural AdvaMed 2007 Conference
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Advances in drug screening: building a better haystack for the needles of tomorrow
8. Advances in Cancer Research, Funding Stem Cell Research, and More at Annual Cancer Congress
9. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
10. Springer adds Advances in Therapy to journals portfolio
11. NIH grant advances dentistry schools work on psychosocial stress
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology: